CHRS:NSD-Coherus BioSciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.24

Change

0.00 (0.00)%

Market Cap

USD 1.17B

Volume

1.39M

Average Target Price

USD 29.50 (+81.65%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Coherus BioSciences, Inc., a biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; Selexis SA; collaboration with Junshi Biosciences; and collaboration with Shanghai Junshi Biosciences, Co., Ltd for the development and commercialization of Toripalimab, Junshi Biosciences' anti-Pd-1 antibody. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Company Website : http://www.coherus.com

Address : 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.36

52 Week High : 22.22

Short Ratio : 8.36

52 Week Low : 10.86

Shorted Shares : 13,080,966

200 Day Moving Average : 18.11

Shorted Shares Previous Month : 13,386,488

50 Day Moving Average : 17.97

Shares Held By Insiders : 16.21%

Short Percentage : 18.00%

Shares Held by Institutions : 125.64%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

 USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

 USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

 USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

 USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing CHRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.56% 23% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.56% 23% F 13% F
Trailing 12 Months  
Capital Gain -16.07% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.07% 21% F 9% F
Trailing 5 Years  
Capital Gain 8.12% 49% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.12% 49% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 0.93% 40% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.93% 40% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 37.59% 73% C 39% F
Risk Adjusted Return 2.48% 40% F 34% F
Market Capitalization 1.17B 73% C 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.02 44% F 74% C
Price/Book Ratio 4.58 61% D- 40% F
Price / Cash Flow Ratio 7.59 10% F 41% F
EV/EBITDA 5.71 39% F 84% B
Management Effectiveness  
Return on Equity 68.49% 100% A+ 99% A+
Return on Invested Capital 32.45% 93% A 95% A
Return on Assets 15.63% 98% A+ 98% A+
Debt to Equity Ratio 134.32% 10% F 16% F
Technical Ratios  
Short Ratio 8.36 17% F 9% F
Short Percent 22.36% 4% F 7% F
Beta 1.36 53% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.